Peking University First Hospital (PKU 1st Hospital) has partnered with China-based health services and distribution giant Baheal Pharmaceutical Group for its integrin-targeted small molecule inhibitor project. The deal, valued at RMB 70 million (USD 9.5 million), grants Baheal exclusive global rights for patent, clinical development and regulatory filing, manufacturing, and market sales of the program.
Research and Discovery
After years of research, the team led by Cui Yimin and Pang Xiaocong from PKU 1st Hospital discovered a high-affinity, non-RGD sequence integrin αvβ3 and α5β1 dual-targeted small molecule inhibitor. This discovery was made using advanced technologies such as virtual screening, surface plasmon resonance, microcalorimetry, and molecular dynamics simulation.
Therapeutic Potential
The inhibitor has shown significant potential in effectively inhibiting drug resistance and bone metastasis progression in prostate cancer, while maintaining good safety. This collaboration aims to accelerate the development and commercialization of this innovative therapy, potentially offering new treatment options for prostate cancer patients.
Significance of the Partnership
This partnership between PKU 1st Hospital and Baheal Pharmaceutical highlights the growing collaboration between academic institutions and industry leaders to advance medical innovations. The deal underscores the potential of integrin-targeted therapies in improving cancer treatment outcomes and expanding the range of available options for patients.-Fineline Info & Tech
Leave a Reply